Protocol # PM1183-C-004-14: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
PharmaMar USA, Inc.
Start Date
August 1, 2015
End Date
September 17, 2019
Administered By
Duke Cancer Institute
Awarded By
PharmaMar USA, Inc.
Start Date
August 1, 2015
End Date
September 17, 2019